It differs from the ADCS-CGIC used in AD trials mainly in its shorter length and its The CGIC rating is made on a 7-point Likert-type scale where change from. Characteristics and performance of a modified version of the ADCS-CGIC CIBIC+ in Alzheimer Disease Assessment Scale-cognitive, Activities of Daily Living. A mandate of the ADCS is to develop optimal assessment instruments for use in Living (ADL), and the Clinical Global Impression of Change Scale (CGIC).
|Published (Last):||6 July 2005|
|PDF File Size:||8.95 Mb|
|ePub File Size:||2.67 Mb|
|Price:||Free* [*Free Regsitration Required]|
The Alzheimer’s Disease Cooperative Study. The Global Deterioration Scale for assessment of primary degenerative dementia.
Additionally, for hypothesis 3, not only does the CGIC change over time, but the values of the predictors clinical variables also change over time.
The dependent variable in the model was the MCI-CGIC scores over time 6 months, 12 months and the independent variables included a treatment factor placebo, vitamin E and donepezila time factor 6 and 12 monthsand the treatment by time interaction. Results were similar whether the 3-category or 2-category model was used Table 2Figure 1. Schneider, Rema Raman, Frederick A. A sharper Bonferroni procedure scaale multiple tests of significance. It is the most frequently used example of a Clinician’s Interview-Based Impression of Change with caregiver’s input i.
There is no association between rate of change ecale MCI-CGIC over 12 months and corresponding change in secondary outcomes listed previously. By comparison, in the present trial at 6 months, Variables at screening or baseline that were associated with worse CGIC scores over 6 and 12 months included white race, greater years of education, worse depression, dementia severity rating, cognitive, and daily activities scores, and lower memory domain scores adcsc-gic a neuropsychological battery.
Vitamin E and donepezil for the treatment of mild cognitive sale.
ADCS Instruments – ADCS
PetersenMD, 8 and Steven H. GEE models for binary data scsle a logistic function and ordinal data using a proportional odds model were used for the two models. To assess the rate of change in MCI-CGIC over 12 months and its association with each of the covariates of interest, the longitudinal analysis was done using a generalized estimating equations GEE approach, which accounts for within-subject correlation.
The Alzheimer’s Disease Assessment Scale. Imputation is done using the last observation carried forward LOCF. Yet, these analyses also suggest that the CGIC, along with the other measures above, may be of more limited sensitivity and use for the more mildly cognitively-impaired MCI patients in clinical trials unless the memory domains are expanded. The ADCS MCI-CGIC was designed to provide a means to assess global change in an MCI clinical trial by providing a semi-structured format to allow clinicians to sdcs-cgic necessary clinical information from both the subject and informant in order to allow for an overall impression of clinical change.
There were no differences between clinic and home ratings. It relies on both direct examination of the patient and interview of informants. Scqle results of the present analyses, using a larger sample size, are similar to the lack of donepezil-placebo statistically significant differences on the CGIC-MCI reported 19 but suggest further that there are various influences on a CGIC rating in MCI in addition to memory New England Journal of Medicine.
The CGICs behaved as expected, showing no overall change over 3 months, no difference between administrations at home compared with clinics, and concurrent validity. Thus, this study provides the first systematic evidence that CGIC ratings, at least in MCI patients, are based on more than assessments of memory. Because there might be differences in CGIC change based on baseline cognitive severity, the sample was split at the median ADAScog point into a higher scoring and lower scoring group.
Weights were calculated as the reciprocal of the sum of the correlation coefficients between the tests adcz-cgic each domain at baseline. Written informed consent was obtained from all participants and study partners. Access to Document The effect size of the donepezil-placebo difference was similar to that of other outcomes at 12 months. FerrisPhD 7. Scoring is based on an interview with the caregiver and examination of the patient by an independent evaluator, without consulting other information such as cognitive test results.
CGIC or ADCS-CGIC:
Although a common approach of analyzing CGIC in clinical trials has been to treat the variable as a continuous scalf, we chose to use the CGIC as an ordinal outcome and take advantage of the ordinal models that are available for such data such as the GEE rather than simply analyzing an ordinal outcome as a continuous outcome.
The GEE method is suitable for the longitudinal analysis of both binary and ordinal outcomes. Morris reports that neither he nor his family own stock or have equity interest outside of mutual funds or other externally directed sca,e in any pharmaceutical or biotechnology company; that from July to the present he has participated or is currently participating in clinical trials of antidementia drugs sponsored by Elan, Eli Lilly and Company, and Wyeth; and from January to the present has served as a consultant or has received speaking honoraria from Bristol-Myers Squibb, Elan, GE Healthcare, Genworth, Janssen-Cilag, Merck, Myriad, Neurochem, Neuroptix, and Schering-Plough.
Further, they suggest that CGIC ratings are influenced by minimal impairments in other areas at baseline along with minimal changes in the primary memory impairments associated with MCI over six months. The coefficients for the LOCF analysis had the same directions as those of the coefficients in the above analysis, with similar odds ratios. This is particularly important when the dependent variable is skewed, or when different adcs-cgi groups are compared which have widely varying skewness of the dependent variables At interval assessments, the subject is interviewed first, followed by the informant.
ADRC – CGIC page
The effect size of the donepezil-placebo difference was similar to that adcs-cgid other outcomes at 12 months. At baseline only, clinical information about the subject may be used, including medical history, physical and neurological examination, and other ratings done at screening. Although CGIC ratings are less precise and consistent than psychometric measures, they may be more sensitive to clinically meaningful effects, and, therefore, can serve as useful measures of clinical utility.
CGIC scales have been used extensively as primary outcomes in phase 2 and 3 clinical trials for Alzheimer disease, mild cognitive impairment, and for cognitive enhancers. An inventory to assess activities of daily living for clinical trials in Alzheimer’s disease. The Alzheimer’s Disease Cooperative Csale. The measures were administered at 6-month intervals over three years except that the ADAS-cog and NTB aadcs-cgic administered at 3 months as well; and the CADQoL was administered at 3 months and then at month intervals from baseline.
The CGIC rating ascs-cgic made on a 7-point Likert-type scale where change from baseline is rated as marked improvement 1moderate improvement 2minimal improvement 3aadcs-cgic change 4minimal worsening 5moderate worsening 6marked worsening 7. The results from the two modeling approaches had clinically similar effects, although the statistical significance differed. Efficacy of donepezil in mild cognitive impairment: We used a generalized estimating equations approach for ordinal outcome data to test the effects of treatment, baseline characteristics and change in clinical measures on the MCI-CGIC over 12 months, and ordinal logistic regression to assess the association between MCI-CGIC and change in clinical measures at 6 months and 12 months.
Because primary prevention trials will require large samples and modest treatment effects are expected, the use of standard clinician-administered, clinic-based measures are unlikely to be feasible.